Marinus (MRNS)
NASDAQ:MRNS

Marinus Stock Analysis & Ratings

MRNS Stock Chart & Stats

Day’s Range$4.92 - $5.13
52-Week Range$4.19 - $19.83
Previous Close$4.9
Volume198.48K
Average Volume (3M)326.07K
Market Cap$185.70M
P/E Ratio-2.0
Beta1.48
Next EarningsAug 11, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score5
EPS (TTM)-2.48


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

MRNS FAQ

What was Marinus’s price range in the past 12 months?
Marinus lowest stock price was $4.19 and its highest was $19.83 in the past 12 months.
    What is Marinus’s market cap?
    Marinus’s market cap is $185.70M.
      What is Marinus’s price target?
      The average price target for Marinus is $29.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $50.00 ,the lowest forecast is $17.00. The average price target represents 490.00% Increase from the current price of $5.
        What do analysts say about Marinus?
        Marinus’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
          When is Marinus’s upcoming earnings report date?
          Marinus’s upcoming earnings report date is Aug 11, 2022 which is in 76 days.
            How were Marinus’s earnings last quarter?
            Marinus released its earnings results on May 12, 2022. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.839 by $0.319.
              Is Marinus overvalued?
              According to Wall Street analysts Marinus’s price is currently Undervalued.
                Does Marinus pay dividends?
                Marinus does not currently pay dividends.
                What is Marinus’s EPS estimate?
                Marinus’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Marinus have?
                Marinus has 37,140,000 shares outstanding.
                  What happened to Marinus’s price movement after its last earnings report?
                  Marinus reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.839. Following the earnings report the stock price went up 16.461%.
                    Which hedge fund is a major shareholder of Marinus?
                    Among the largest hedge funds holding Marinus’s share is RA Capital Management. It holds Marinus’s shares valued at N/A.

                      ---

                      Marinus Stock Analysis

                      The Marinus stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Marinus

                      Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Supernus Pharmaceuticals
                      SAGE Therapeutics
                      Ovid Therapeutics
                      Zynerba Pharmaceuticals
                      Eisai Co

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis